ixekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5083 1143503-69-8

Description:

MoleculeDescription

Synonyms:

  • ixekizumab (genetical recombination)
  • ixekizumab
  • LY2439821
  • taltz
A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.90 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 4, 2016 PMDA Eli Lilly Japan
Feb. 25, 2016 EMA
March 22, 2016 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 582.34 25.28 286 9605 74650 50520583
Injection site pain 521.58 25.28 303 9588 110721 50484512
Therapy interrupted 490.55 25.28 174 9717 19978 50575255
Injection site reaction 486.40 25.28 223 9668 49809 50545424
Injection site swelling 485.44 25.28 211 9680 41562 50553671
Therapy cessation 294.01 25.28 129 9762 25882 50569351
COVID-19 236.02 25.28 134 9757 46528 50548705
Injection site urticaria 172.48 25.28 71 9820 12146 50583087
Injection site pruritus 172.45 25.28 104 9787 40307 50554926
Injection site warmth 154.06 25.28 68 9823 13798 50581435
Psoriasis 141.19 25.28 113 9778 68887 50526346
Injection site rash 140.96 25.28 67 9824 16110 50579123
Drug ineffective 120.93 25.28 391 9500 818942 49776291
Ear infection 108.56 25.28 66 9825 25904 50569329
Sinusitis 86.27 25.28 134 9757 170424 50424809
Tooth infection 64.50 25.28 38 9853 14074 50581159
Nasopharyngitis 64.11 25.28 126 9765 192801 50402432
Pharyngitis streptococcal 63.29 25.28 32 9859 8776 50586457
Fungal infection 63.18 25.28 50 9841 29915 50565318
Psoriatic arthropathy 61.88 25.28 60 9831 46972 50548261
Injection site mass 60.80 25.28 38 9853 15642 50579591
Urticaria 57.51 25.28 96 9795 129465 50465768
Product dose omission issue 57.39 25.28 117 9774 183721 50411512
Injection site bruising 54.27 25.28 50 9841 36718 50558515
Infection 50.37 25.28 107 9784 172847 50422386
Inappropriate schedule of product administration 50.33 25.28 66 9825 71765 50523468
Illness 47.59 25.28 39 9852 24501 50570732
SARS-CoV-2 test positive 45.83 25.28 21 9870 4638 50590595
Surgery 40.59 25.28 39 9852 30166 50565067
Urinary tract infection 40.09 25.28 115 9776 223905 50371328
Therapy non-responder 39.06 25.28 49 9842 50973 50544260
Accidental underdose 38.07 25.28 11 9880 647 50594586
Chronic disease 35.16 25.28 7 9884 80 50595153
Pruritus 34.83 25.28 128 9763 283440 50311793
Injection related reaction 34.53 25.28 10 9881 593 50594640
Influenza 34.03 25.28 62 9829 89476 50505757
Acute kidney injury 33.57 25.28 3 9888 228055 50367178
Upper respiratory tract infection 33.53 25.28 52 9839 65846 50529387
Inflammatory bowel disease 32.22 25.28 15 9876 3435 50591798
Wrong technique in device usage process 30.22 25.28 13 9878 2473 50592760
Demyelinating polyneuropathy 30.10 25.28 9 9882 597 50594636
Injection site cellulitis 27.97 25.28 10 9881 1165 50594068
Hypotension 27.88 25.28 6 9885 235463 50359770
Candida infection 27.21 25.28 28 9863 23495 50571738

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site pain 397.00 31.33 171 5752 32275 29536329
Injection site reaction 381.22 31.33 125 5798 11063 29557541
Injection site erythema 323.82 31.33 117 5806 13839 29554765
Injection site swelling 256.55 31.33 89 5834 9328 29559276
Therapy interrupted 223.55 31.33 78 5845 8308 29560296
Therapy cessation 205.70 31.33 85 5838 14377 29554227
Psoriasis 203.61 31.33 108 5815 32119 29536485
Drug ineffective 143.07 31.33 257 5666 362913 29205691
COVID-19 127.47 31.33 83 5840 35931 29532673
Injection site pruritus 106.08 31.33 41 5882 5808 29562796
Injection site rash 94.31 31.33 33 5890 3531 29565073
Nasopharyngitis 90.25 31.33 83 5840 59582 29509022
Ear infection 83.58 31.33 38 5885 8062 29560542
Sinusitis 68.51 31.33 56 5867 34294 29534310
Infection 66.03 31.33 79 5844 76672 29491932
Pruritus 57.75 31.33 92 5831 116757 29451847
Influenza 57.00 31.33 55 5868 41826 29526778
Injection site warmth 56.25 31.33 19 5904 1827 29566777
Injection site urticaria 50.90 31.33 17 5906 1579 29567025
Inappropriate schedule of product administration 47.05 31.33 51 5872 44421 29524183
Psoriatic arthropathy 45.01 31.33 31 5892 14660 29553944
Wrong technique in device usage process 44.55 31.33 14 5909 1071 29567533
Injection site bruising 43.82 31.33 24 5899 7556 29561048
Product dose omission issue 43.65 31.33 73 5850 96310 29472294
Insurance issue 42.19 31.33 13 5910 932 29567672
SARS-CoV-2 test positive 42.17 31.33 18 5905 3281 29565323
Ejection fraction decreased 40.40 31.33 30 5893 15948 29552656
Fungal infection 39.87 31.33 28 5895 13657 29554947
Injection site mass 39.27 31.33 20 5903 5435 29563169
Rash 39.05 31.33 104 5819 189715 29378889
Acute kidney injury 38.99 31.33 4 5919 265263 29303341
Therapy non-responder 37.23 31.33 38 5885 30873 29537731
Intestinal haemorrhage 36.73 31.33 16 5907 3063 29565541
Cellulitis 35.82 31.33 45 5878 45795 29522809
Illness 35.48 31.33 20 5903 6654 29561950
Arthralgia 33.35 31.33 81 5842 139536 29429068
Knee operation 32.78 31.33 12 5911 1460 29567144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 763.06 23.92 235 10862 19801 64467834
Injection site erythema 439.52 23.92 223 10874 70577 64417058
Injection site pain 429.26 23.92 256 10841 111152 64376483
Injection site swelling 419.78 23.92 183 10914 41170 64446465
Therapy cessation 400.27 23.92 165 10932 32324 64455311
Injection site reaction 395.42 23.92 182 10915 46482 64441153
COVID-19 360.44 23.92 190 10907 64950 64422685
Ear infection 187.77 23.92 88 11009 23316 64464319
Sinusitis 173.56 23.92 166 10931 145762 64341873
Psoriasis 159.04 23.92 117 10980 71586 64416049
Injection site pruritus 145.38 23.92 87 11010 37739 64449896
Nasopharyngitis 134.65 23.92 167 10930 195906 64291729
Injection site warmth 134.48 23.92 59 11038 13403 64474232
Psoriatic arthropathy 110.54 23.92 77 11020 43204 64444431
Drug ineffective 109.61 23.92 354 10743 839893 63647742
Injection site urticaria 108.43 23.92 48 11049 11133 64476502
Injection site rash 107.44 23.92 53 11044 15689 64471946
Illness 101.65 23.92 57 11040 21881 64465754
Infection 96.84 23.92 138 10959 184742 64302893
Product dose omission issue 89.92 23.92 137 10960 194610 64293025
Fungal infection 80.64 23.92 58 11039 34193 64453442
SARS-CoV-2 test positive 74.15 23.92 31 11066 6255 64481380
Pharyngitis streptococcal 73.85 23.92 34 11063 8634 64479001
Tooth infection 70.53 23.92 39 11058 14562 64473073
Surgery 69.23 23.92 49 11048 28164 64459471
Inappropriate schedule of product administration 65.43 23.92 80 11017 92206 64395429
Acute kidney injury 53.70 23.92 7 11090 449233 64038402
Drug interaction 50.36 23.92 3 11094 362080 64125555
Wrong technique in device usage process 47.16 23.92 18 11079 2864 64484771
Injection site bruising 46.20 23.92 43 11054 36330 64451305
Pruritus 43.38 23.92 135 10962 312265 64175370
Cellulitis 43.29 23.92 66 11031 93591 64394044
Inflammatory bowel disease 42.44 23.92 19 11078 4519 64483116
Injection site mass 42.37 23.92 30 11067 17240 64470395
Intentional dose omission 41.46 23.92 20 11077 5632 64482003
Product dispensing error 40.52 23.92 25 11072 11425 64476210
Upper respiratory tract infection 40.49 23.92 56 11041 72729 64414906
Hypotension 38.82 23.92 9 11088 380965 64106670
Wrong schedule 36.87 23.92 9 11088 313 64487322
Localised infection 35.14 23.92 34 11063 30127 64457508
Manufacturing product shipping issue 35.08 23.92 7 11090 93 64487542
Chronic disease 34.81 23.92 7 11090 97 64487538
Influenza 34.45 23.92 64 11033 106467 64381168
Insurance issue 33.54 23.92 14 11083 2812 64484823
Bronchitis 31.08 23.92 62 11035 108681 64378954
Injection related reaction 30.38 23.92 9 11088 658 64486977
Rash 30.21 23.92 157 10940 458392 64029243
Urinary tract infection 30.19 23.92 98 10999 231498 64256137
Intestinal haemorrhage 30.16 23.92 16 11081 5498 64482137
Urticaria 29.67 23.92 73 11024 147244 64340391
Spinal operation 28.57 23.92 16 11081 6117 64481518
Product distribution issue 28.35 23.92 9 11088 829 64486806
Skin disorder 26.39 23.92 28 11069 27652 64459983
Antibiotic therapy 25.06 23.92 8 11089 751 64486884
Confusional state 24.98 23.92 7 11090 261137 64226498
Oral candidiasis 24.87 23.92 25 11072 23187 64464448
Device malfunction 24.64 23.92 22 11075 17611 64470024
Oropharyngeal pain 24.59 23.92 50 11047 88817 64398818

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC13 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
MeSH PA D003879 Dermatologic Agents
FDA MoA N0000191494 Interleukin-17A Antagonists
FDA EPC N0000191495 Interleukin-17A Antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Psoriatic arthritis indication 156370009 DOID:9008
Plaque psoriasis indication 200965009
Pustular psoriasis indication 200973000
Erythrodermic psoriasis indication 200977004
Non-radiographic axial spondyloarthritis indication 713777005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-17A Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
BTY153760O UNII
D10071 KEGG_DRUG
4035606 VANDF
C3489764 UMLSCUI
CHEMBL1743034 ChEMBL_ID
DB11569 DRUGBANK_ID
9467 INN_ID
C549079 MESH_SUPPLEMENTAL_RECORD_UI
7541 IUPHAR_LIGAND_ID
1745099 RXNORM
31578 MMSL
d08425 MMSL
724037000 SNOMEDCT_US
763603002 SNOMEDCT_US
016752 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-1445 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-1445 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-7724 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-7724 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections